Eisai America, Inc.

Nihon Eisai Co., Ltd.'s contraceptive suppository : Sampoon : , researched and developed during Japan's postwar baby boom, receives official approval from the Japanese government.

Nihon Eisai Co., Ltd. launches cardiotonic : Neophyllin : in Japan.

Nihon Eisai Co., Ltd. launches high-dosage vitamin B1 and B2 product : Chocola BB Tablets : in Japan.

Nihon Eisai Co., Ltd. launches motion sickness remedy : Travelmin : in Japan.

The company changes its name from Nihon Eisai Co., Ltd. to Eisai Co., Ltd., as it is known today.

Eisai rolls out its first three-year mid-term plan.

Eisai's Head Office building is completed in Tokyo.

Eisai opens its Taipei Office (now part of Eisai Taiwan Inc.), the company's first overseas branch, in Taiwan.

Eisai is publicly listed in the First Section of both the Tokyo and Osaka Stock Exchanges.

Gastrointestinal remedies : Saclon : and : Saclon Tablets : , recognizable for their distinct green hue even today, are launched in Japan.

Toyoji Naito receives the Japan Marketing Award, which recognizes people who have made a significant contribution to marketing and advertising in Japan.

The Kawashima Plant is completed in Gifu, central Japan.

Kawashima Plant opening ceremony.

Founder Toyoji Naito is appointed as chairman and Yuji Naito as company president.

A three-tier representative director system is introduced: Chairman Toyoji Naito, President Yuji Naito, and Executive Vice President Tatsuo Naito.

Youda Co., Ltd. is established as a pharmaceutical imports subsidiary in Taiwan.

PT Eisai Indonesia is established as a pharmaceutical manufacturing and sales subsidiary in Indonesia.

Toyoji Naito resigns as representative director and chairman to assume director and honorary chairman roles.

Toyoji opens the Naito Museum of Pharmaceutical Science and Industry, Japan's first pharmaceutical museum, in Gifu.

Eisai (Malaysia) Sdn. Bhd. and Hi-Eisai Pharmaceutical Inc. are established as pharmaceutical sales subsidiaries in Malaysia and the Philippines, respectively.

Metabolic cardiotonic : Neuquinon : is launched in Japan.

Naturally derived vitamin E product : Juvelux : is launched in Japan.

Eisai's founder Toyoji Naito passes away at age 89.

Peripheral neuropathy treatment : Methycobal : is launched in Japan.

Eisai Asia Regional Services Pte. Ltd. is established as a sales support and management services subsidiary in Singapore.

Eisai America, Inc. is established as a clinical research subsidiary in New Jersey, the United States.

Eisai Inc. North Carolina Plant is established as a pharmaceutical manufacturing and formulation R&D facility at Research Triangle Park in North Carolina, the United States.

Anti-Alzheimer's agent : Aricept : is launched in the United States, the United Kingdom and Germany.

Pariet : is launched under the brand name : AcipHex : in the United States.

Eisai Medical Research Inc. is established as a clinical research subsidiary in New Jersey, the United States.

Eisai acquires four anticancer agents from Ligand Pharmaceuticals Inc. in the United States.

Eisai acquires Morphotek Inc., a bioventure specialized in antibody research, in the United States.

Eisai acquires MGI Pharma Inc., an oncology biopharmaceutical company in the United States.

Halaven is launched in the United States.

H3 Biomedicine Inc. is established as a research subsidiary in the United States.

Fycompa is launched in the United States.

Lenvima is launched in the United States, Japan and Europe.

Collaboration agreement with Biogen to develop and commercialize investigational Alzheimer's disease treatments including aducanumab expanded.

Eisai agrees upon a strategic collaboration for Lenvima with Merck & Co., Inc., Kenilworth, N.J., U.S.A.

Eisai Center for Genetics Guided Dementia Discovery (G2D2) in Massachusetts, U.S., commences full-scale operation.

DAYVIGO (insomnia treatment) is launched in the United States and Japan.

Alzheimer’s disease treatment LEQEMBI is granted accelerated approval and launched in the United States.

LEQEMBI is granted traditional approval by the FDA.